Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Celgene Corp

(NASDAQ: CELG)
Add to Portfolio
-0.43 (-0.39%)
as of 09:53 EST

Last 109.59
Change -0.43 (-0.39%)
Open 109.99
Prev. Close 110.02
Today's Range
109.35
110.43
52wk Range
58.59
110.70
Volume 1,832,937
Avg Volume 4,177,296
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
CELG -0.39% +13.02% +57.52%
DJIA -0.01% +4.28% +10.11%
S&P 500 -0.18% +4.51% +13.76%

Key Statistics

Annual EPS 8.12
Dividend Yield 0.00%
P/E Ratio 11.08
Market Capitalization, $K 77,576,883
Weighted Alpha +45.04
Standard Deviation -0.61
Profit Margin 24.03%
Beta 1.41

Growth Rates

YTD +71.18%
1-Year +57.96%
3-Year -9.80%
5-Year +1.68%
10-Year +296.83%

Opinion

Sell Hold Buy

Recent Headlines

Bristol-Myers Squibb Company Announces It Expects No

BusinessWire via COMTEX - Fri Nov 15, 06:39PM EST
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that it currently expects there will be no further extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Cel(full story)
CELGZ: 0.44 (-0.04), BMY: 57.74 (-0.85), CELG: 109.59 (-0.43)

Bristol-Myers Squibb Receives Clearance from U.S.

BusinessWire via COMTEX - Fri Nov 15, 04:55PM EST
--Transaction Expected to Close on November 20, 2019(full story)
CELGZ: 0.44 (-0.04), BMY: 57.74 (-0.85), CELG: 109.59 (-0.43), AMGN: 220.66 (-0.20)

Celgene Receives CHMP Positive Opinion for REVLIMID(R)

BusinessWire via COMTEX - Fri Nov 15, 07:30AM EST
--The positive opinion was based on the results of the Phase 3 AUGMENT study, which showed the R(2) regimen conferred a statistically significantly improvement in progression-free survival versus rituximab monotherapy(full story)
CELGZ: 0.44 (-0.04), CELG: 109.59 (-0.43)

Bristol-Myers Squibb Company Announces Extension of

BusinessWire via COMTEX - Fri Nov 15, 06:59AM EST
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene Corporation (NAS(full story)
CELGZ: 0.44 (-0.04), BMY: 57.74 (-0.85), CELG: 109.59 (-0.43)

Celgene Corp Rises 9.25% on Heavy Volume: Watch For

Comtex SmarTrend(R) via COMTEX - Tue Nov 12, 12:21PM EST
Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $109.40 to a high of $109.78. Yesterday, the shares gained 9.3%, which took the trading range above the 3-day high of $109.75 on volume of 202,000(full story)
CELG: 109.59 (-0.43)